Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy

American Journal of Surgical Pathology

Volumn 20, Issue 3, 1996, Pages 306-312

  Randhawa, P S ^a,c   Tsamandas, A C ^a   Magnone, M ^a   Jordan, M ^a   Shapiro, R ^a   Starzl, T E ^b   Demetris, A J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Allografts; FK506; Kidney; Tacrolimus; Thrombi; Toxicity

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; THROMBUS;

ADULT; AGED; ARTERIOLES; CAPILLARIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RENAL CIRCULATION; TACROLIMUS; THROMBOSIS;

EID: 0030071092     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199603000-00007     Document Type: Article

References (29)

1. Demetris AJ, Fung JJ, Todo S, Banner B, Zerbe T, Sysyn G, Starzl TE. Pathologic observations in human allograft recipients treated with FK506. Transplant Proc 1990;22(suppl 1): 25-34.
2. Erden E, Warty V, Magnone M, Shapiro R, Demetris J, Randhawa P. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection [Letter]. Transplantation 1994;58:397-8.
3. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver rejection. Lancet 1994;344:423-8.
4. Fries D, Rucay P, Samuel D, et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK506 for acute rejection following liver transplantation. Transplant Proc 1991;23:3099-100.
5. Hill GS. Systemic lupus erythematosus and mixed connective tissue disease. In: Heptinstall RH, ed. Pathology of the kidney. Boston: Little Brown, 1992:884-5.
6. Holman MJ, Gonwa TA. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1992;55:205-6.
7. Japanese FK506 study group. Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK506. Transplant Proc 1991;23:3111-5.
8. Japanese FK 506 study group. Morphological characteristics of renal allografts showing renal dysfunction under FK506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK506 nephropathy? Transplant Proc 1993;25:624-7.
9. Kant KS, Pollak VE, Weiss MA, Glueck H, Miller MA, Hess EV. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine 1981;60:71-86.
10. Kerns WD, Arena E, Morgan DG. Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by Fenoldopam mesylate and dopamine in the rat. Am J Pathol 1989;135:339-49.
11. Kumano K, Wang G, Endo T, Kuwao S. FK506-induced nephrotoxicity in rats. Transplant Proc 1991;23:512-5.
12. Lieberman KV, Lin WG, Reisman L. FK506 is a direct glomeruloconstrictor as determined by electric resistance pulse sizing. Transplant Proc 1991;23:3119-20.
13. McCauley J, Bronsther O, Fung J, Todo S, Starzl TE. Treatment of cyclosporine induced hemolytic uremic syndrome with FK506 [Letter]. Lancet 1989;2:1516.
14. McCauley J, Fung JJ, Todo S, Jain A, Deballi P, Starzl TE. Changes in renal function after liver transplantation under FK506. Transplant Proc 1991;23:3143-5.
15. Mihatsch MJ, Ryffel B, Gudat F, Thiel G. Cyclosporine nephropathy. In: Tisher CC, Brenner BM, ed. Renal pathology with clinical and functional correlations. Philadelphia: JB Lippincott, 1989:1570-5.
16. Nalesnik MA, Todo S, Murase N, Gryzan S, Lee PH, Makowka L, Starzl TE. Toxicology of FK506 in the Lewis rat. Transplant Proc 1987;5:89-92.
17. Ochiai T, Sakamoto K, Gunji Y, et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. Transplantation 1989;48:193-7.
18. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;4:746-94.
19. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Am J Surg Pathol 1993;17:60-8.
20. Schmidt RJ, Venkat KK, Dumler F. Hemolytic-uremic syndrome in a renal transplant recipient on FK506 immunosuppression. Transplant Proc 1991;23:3156-7.
21. Shapiro R, Jordan M, Scantlebury V, et al. FK506 in clinical kidney transplantation. Transplant Proc 1991;23:3065-7.
22. Shulman H, Striker G, Deeg HJ, Kennedy M, Storb R, Thomas ED. Nephrotoxicity of cyclosporine A after allogeneic marrow transplantation. Glomerular thrombosis and tubular injury. N Engl J Med 1981;305:1392-5.
23. Thiru S, Collier DSJ, Calne R. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK506. Transplant Proc 1987;14:98-9.
24. Todo S, Demetris AJ, Ueda Y, et al. Canine kidney transplantation with FK506 alone or in combination with cyclosporine and steroids. Transplant Proc 1987;14:57-61.
25. Todo S, Ueda Y, Demetris AJ, et al. Immunosuppression of canine, monkey, and baboon allografts by FK506: with special reference to synergism with other drugs and to tolerance induction. Surgery 1988;104:239-19.
26. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331: 1110-5.
27. Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985;98:54-62.
28. Wang SC, Morel PA, Wang Q, Jordan ML, Simmons RL, Tweardy J. A dual mechanism of immunosuppression by FK506: differential suppression of 1L-4 and IL10 levels in T helper 2 cells. Transplantation 1993;56:978-85.
29. Yamada K, Sugisaki Y, Akimoto M, Yamanaka N. Short-term FK506 induced morphological changes in rat kidneys. Transplant Proc 1991;23:3130-2.